How do we operate?

The PVRI is a registered charity in the UK with the Charity Commission. It is also a limited company by guarantee, registered with the UK Companies House. It is governed by a group of Trustees who form the Council of the PVRI. The PVRI’s constitution, including our mission statement and how each of our departments work, can be viewed by clicking on the button below.

PVRI's structure

PVRI Structure & Governance

Council of the PVRI/Board of Trustees

Paul Corris (Trustee & Chair of the Board)

Paul Corris is Emeritus Professor of Thoracic Medicine and faculty member of the Institute of Cellular Medicine at Newcastle University.

He holds an honorary consultant physician contract at The Newcastle Hospitals NHS Foundation Trust (Newcastle Upon Tyne, UK) and directed the National Pulmonary Vascular Service (NPVS) in Newcastle, being one of a small group who set up the UK National Service in 2001.

He played a major international role in establishing lung transplantation as a viable clinical entity and directed the NPVS from 2012 to 2017. Paul is also a Past-President of both the British Thoracic Society and the International Society for Heart and Lung Transplantation.

He was President of the Pulmonary Vascular Research Institute for and also held the position of PVRI Chief Medical Scientific Officer for the 2018/19 term, as well currently acting as the Chair of the PVRI Interim Board of Directors.

He has been a faculty member and author of guidelines within his speciality interests for many societies and world health groups. His research has been highly cited and is focused on translational and clinical science relating to both lung transplantation and pulmonary hypertension.

He has a wide experience of very successful committee work and his background would make him a suitable candidate for the Science Committee of the WHF. He has an unrivalled global reputation for his energy, wisdom, integrity and clarity of thinking, with an uncanny ability to bring groups together to achieve a common aim.

Publications

Accolades

  • Recipient of the British Thoracic Society Medal 2018, in recognition of his leadership in and contribution to clinical and scientific work resulting in benefit to patients and the inspiration of peers.
  • Received the 2018 PVRI Life Achievement Award for his significant contribution in the field of pulmonary hypertension.

Werner Seeger (PVRI President 2020/21)

Professor Seeger is based at the Department of Internal Medicine, Justus Liebig University, Giessen, where he is the Medical Executive Director of the University Hospital, Giessen and Marburg.

His main areas of research include pulmonary circulation, acute lung injury, pneumonia and sepsis, chronic respiratory failure and aerosol medicine.

He has held numerous academic posts and is currently:

Publications

Accolades

Stephanie Barwick (Chief Executive & Company Secretary)

Stephanie is a passionate, outgoing and innovative business executive with experience spanning over different industries, countries and cultures. She has held senior positions in the public, private and charitable sectors, where she gained extensive senior leadership experience and knowledge in entrepreneurship, business start-up and not-for-profit management. She is an outstanding communicator and skilled networker who can shape organisational strategy into meaningful operational plans and lead organisations through major transformation and change.

Stephanie joined the PVRI in April 2014 as its first external Chief Executive. Since then she has transformed the organisation into a global medical society with an international reputation. She has driven the growth of PVRI memberships from 400 to over 7,500 in 104 different countries, increased the Institute’s annual income by over 200% and overseen the publication of more than 800 articles. She is highly skilled at delivering effective governance, managing diverse stakeholders and driving business transformation that increases participation, improves efficiencies and achieves a greater impact on the charitable mission.

In her previous position at the University of Kent, she was awarded the prestigious ‘Barbara Morris Prize’ in recognition of her outstanding achievements and services to student employability. 

Stephanie is fluent in four languages and holds degrees from Munich University in Germany and a recent first-class Executive Master’s Degree in Business Administration (MBA) from the University of Warwick, UK, currently ranked 6th best worldwide. With a strong altruistic mindset and purpose-driven attitude, she is a charismatic and caring leader who displays a great sense of integrity, responsibility and humility.

Accolades

Stuart Rich (Founder & Trustee)

Dr. Stuart Rich MD is a cardiologist and Director of Pulmonary Vascular Disease Programme at the Bluhm Cardiovascular Institute and a Professor at Northwestern University’s Feinberg School of Medicine.

He is one of the world’s most recognised experts on pulmonary vascular diseases. For more than three decades he has dedicated his research and clinical efforts to finding better solutions for pulmonary hypertension. Dr. Rich completed his residency training in medicine at Washington University in St Louis, and fellowship in cardiology at the University of Chicago.

His career began at the University of Illinois, where he was the principal investigator for the National Institutes of Health’s (NIH) Registry on Primary Pulmonary Hypertension, the first of its kind, and has been the leader of the largest clinical centre in the US for evaluating and treating patients with pulmonary hypertension since 1980.

Dr. Rich has conducted cutting-edge research on the molecular mechanisms and epidemiology; clinical presentation, natural history, and has been at the forefront of the development of virtually every new form of pulmonary hypertension treatment. His pioneering research has led to a greater understanding of all types/stages of pulmonary hypertension, as well as the use of new therapeutic procedures and devices.

Martin Wilkins (Trustee & Treasurer)

Martin R. Wilkins MD (FRCP FBPhS FMedSci) is Head of Department of Medicine, Imperial College, London, and is a physician-scientist with a background in clinical pharmacology and toxicology. 

He has spent the past 25 years investigating the molecular pathology of pulmonary hypertension with a view to identifying novel drug targets and better ways of monitoring pulmonary vascular disease. 

He has published widely on the cyclic GMP signalling pathway and circulating biomarkers. More recently he has investigated the role of iron homeostasis and zinc transport in pulmonary vascular disease. 

His research is supported by the British Heart Foundation, Medical Research Council, the Wellcome Trust and the National Institute of Health Research.

Gérald Simonneau (Trustee)

Professor Gérald Simonneau is an Emeritus Professor at the Paris-Sud University, France, and Senior Consultant at the National Reference Centre for Pulmonary Vascular Disease in Bicetre and Marie Lannelongue University Hospitals, France.

He has been President of the working group on pulmonary circulation of the European Society of Cardiology

Publications

Professor Simonneau has been published widely in the fields of pulmonary hypertension, pulmonary vascular diseases and pneumology. Peer-reviewed journals he has featured in include:

Accolades

Paul Hassoun (Trustee)

Dr. Paul M Hassoun is a Professor of Medicine at the Johns Hopkins University School of Medicine in the USA. His areas of clinical expertise include pulmonary disease and critical care medicine. 

Dr. Hassoun earned his MD from the Faculté de Médecine Lariboisière-Saint Louis (Paris VII, France) and completed a residency in Internal Medicine at Brigham Women's Hospital, as well as a Pulmonary and Critical Care fellowship at Massachusetts General Hospital (both at Harvard Medical School, Boston).

Dr. Hassoun serves as the Director of the Pulmonary Hypertension Programme, a large clinical programme dedicated to the diagnosis and treatment, in a multidisciplinary fashion, of all five disease groups from the World Classification of Pulmonary Hypertension (PH).

Over the past two decades, Dr Hassoun has led programmatic efforts for clinical and basic research in PH. Dr. Hassoun's research interests include pulmonary arterial hypertension (PAH) with a focus on highly translational research to understand the complex pathobiology of scleroderma-associated PAH, and acute lung injury.

He is a member of numerous professional organisations, including the American Thoracic Society, the European Respiratory Society, and the American Heart Association, not to mention serving as PVRI President during the 2018/19 term.

Bert van den Bergh (Trustee)

Bert van den Bergh is President of Revalesio Corporation where he leads the development and commercialisation of the company’s RNS60 therapeutic.

He holds a bachelor’s degree in business administration from Nijenrode Business School (The Netherlands) and an MBA from Interfaculty Delft/Rotterdam, now the Rotterdam School of Management (The Netherlands).

Bert has a proven track record of successfully commercialising novel medicines and has led business operations at major pharmaceutical companies around the world. He started his career at Eli Lilly & Company, working his way up to multiple senior executive positions across the company’s US and European operations.

Most notably, he served as President of Neuroscience Products, President of European Operations and General Manager for the UK and Germany. In these roles, Bert was instrumental in the development, commercialisation, and lifecycle management of innovative pharmaceuticals like Cymbalta, Prozac, Strattera and Zyprexa. 

Most recently, Bert served as Chairman of the Board at Correvio, LLC. In addition to his role at Revalesio, Bert serves on a variety of non-profit boards and advisory committees, including the PVRI, Mental Health America and Peers for Progress.

Magdi Yacoub (Chair of the Medical Advisory Board)

Sir Magdi Yacoub (OM FRS) is Executive Director of the Qatar Cardiovascular Research Centre in collaboration with the Qatar Foundation, Magdi Yacoub Research Network and Hamad Medical Corporation

He is also Professor of Cardiothoracic Surgery at the National Heart and Lung Institute, Imperial College London, as well as Founder and Director of Research at Harefield Heart Science Centre (Magdi Yacoub Institute). Across both of these roles, he oversees 60 scientists and students focused on tissue engineering, myocardial regeneration, stem cell biology, end-stage heart failure and transplant immunology. 

Professor Yacoub established the largest heart and lung transplantation programme in the world where more than 2,500 transplant operations have been performed. He has also developed novel operations for a number of complex congenital heart anomalies, as well as leading research including tissue engineering heart valves, myocardial regeneration; novel left ventricular assist devices and wireless sensors with collaborations within

Sir Magdi has an active interest in global healthcare delivery, with a focus not only on Imperial College and domestic matters, but internationally too. He has spearheaded developing programmes in Egypt, The Gulf Region, Mozambique, Ethiopia and Jamaica.

As well as his current role at the PVRI, Sir Magdi is Founder and President of the Chain of Hope charity, treating children with correctable cardiac conditions from developing countries and establishing training and research programmes in local cardiac units.

Accolades

Nick Morrell (Editor-in-Chief of Pulmonary Circulation)

Nick Morrell MD (ScD FRCP FMedSci) qualified in Medicine (MB BS) from Charing Cross and Westminster Medical School (now Imperial College, London) in 1987.

He undertook his research MD at Charing Cross Hospital and then spent two years in Denver, Colorado, as a British Heart Foundation fellow before returning as a Lecturer to complete training in General and Respiratory Medicine at the Royal Postgraduate Medical School, Hammersmith Hospital.

He was appointed Senior Lecturer and Honorary Consultant at Hammersmith Hospital, Imperial College in 1998 and was awarded an MRC Clinician Scientist Fellowship. He moved to the University of Cambridge in 2000 as University Lecturer and Honorary Consultant at Addenbrooke’s and Papworth Hospitals, and was appointed Professor of Cardiopulmonary Medicine in 2007.

In 2009, he was awarded a British Heart Foundation Professorship and in 2011 elected to the fellowship of the Academy of Medical Sciences of the UK. He has chaired the programme committees for the British and American Thoracic Societies. He has served on the MRC Clinical Fellowships Committee and was Director of the BHF Cambridge Centre for Cardiovascular Research Excellence (2014-2019).

His current work includes:

Nick has published over 220 papers in this field. More recently, he has been involved in exciting new genomics initiatives in the UK to apply whole genome sequencing to understanding the genetic basis of rare diseases; including pulmonary arterial hypertension and applying this technology to the direct care of patients. 

Ghazwan Butrous (Founder & President Emeritus)

Dr Ghazwan Butrous was a founding member of the Pulmonary Vascular Institute back in 2006 and was awarded the chair of Cardiopulmonary Science at the University of Kent in the same year.

He graduated from Baghdad Medical College in 1976. From 1980 to 1990, he worked in London where he was a fellow and lecturer of Cardiology at St Bartholomew's Hospital Medical School & St George's Hospital Medical School. He was also director of the Cardiac Electrophysiology Laboratory at St George's from 1985 to 1990.

In 1991 he became Senior Lecturer at the St George's Hospital Medical School and Chief Scientific Adviser for Pfizer Research and Development Laboratories in Sandwich, UK. Dr Butrous has been vitally interested in academia and research since he was a medical student, spurring him to create the PVRI.